Cardiol Therapeutics Inc Class A - Asset Resilience Ratio

Latest as of December 2025: 90.67%

Cardiol Therapeutics Inc Class A (CRDL) has an Asset Resilience Ratio of 90.67% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Cardiol Therapeutics Inc Class A strategic capital allocation to assess the company's strategic physical and investment asset allocation.

Liquid Assets

CA$21.42 Million
≈ $15.49 Million USD Cash + Short-term Investments

Total Assets

CA$23.62 Million
≈ $17.09 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2017–2025)

This chart shows how Cardiol Therapeutics Inc Class A's Asset Resilience Ratio has changed over time. See CRDL net asset quality score to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Cardiol Therapeutics Inc Class A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Cardiol Therapeutics Inc Class A market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CA$21.42 Million 90.67%
Short-term Investments CA$0.00 0%
Total Liquid Assets CA$21.42 Million 90.67%

Asset Resilience Insights

  • Very High Liquidity: Cardiol Therapeutics Inc Class A maintains exceptional liquid asset reserves at 90.67% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Cardiol Therapeutics Inc Class A Industry Peers by Asset Resilience Ratio

Compare Cardiol Therapeutics Inc Class A's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Vivesto AB
ST:VIVE
Drug Manufacturers - Specialty & Generic 17.16%
CHRISTINA LAKE CANNABIS
F:CLB
Drug Manufacturers - Specialty & Generic 0.19%
Turk Ilac ve Serum Sanayi AS
IS:TRILC
Drug Manufacturers - Specialty & Generic 0.00%
Moberg Pharma AB (publ)
ST:MOB
Drug Manufacturers - Specialty & Generic 4.15%
Canopy Growth Corp
NASDAQ:CGC
Drug Manufacturers - Specialty & Generic 0.45%
Zhejiang Nhu Co Ltd
SHE:002001
Drug Manufacturers - Specialty & Generic 4.97%
CONSUN PHARMAC.GR.HD -10
F:C1P
Drug Manufacturers - Specialty & Generic 41.64%
Aarey Drugs & Pharmaceuticals Limited
NSE:AAREYDRUGS
Drug Manufacturers - Specialty & Generic 0.34%

Annual Asset Resilience Ratio for Cardiol Therapeutics Inc Class A (2017–2025)

The table below shows the annual Asset Resilience Ratio data for Cardiol Therapeutics Inc Class A.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 90.67% CA$21.42 Million
≈ $15.49 Million
CA$23.62 Million
≈ $17.09 Million
-5.30pp
2024-12-31 95.97% CA$30.58 Million
≈ $22.12 Million
CA$31.86 Million
≈ $23.05 Million
+0.62pp
2023-12-31 95.35% CA$34.99 Million
≈ $25.31 Million
CA$36.70 Million
≈ $26.55 Million
-0.63pp
2022-12-31 95.97% CA$59.53 Million
≈ $43.06 Million
CA$62.03 Million
≈ $44.87 Million
+0.43pp
2021-12-31 95.54% CA$83.96 Million
≈ $60.74 Million
CA$87.88 Million
≈ $63.57 Million
+6.91pp
2020-12-31 88.63% CA$14.09 Million
≈ $10.19 Million
CA$15.89 Million
≈ $11.50 Million
+43.37pp
2019-12-31 45.27% CA$7.02 Million
≈ $5.08 Million
CA$15.50 Million
≈ $11.21 Million
-22.52pp
2018-12-31 67.78% CA$16.73 Million
≈ $12.10 Million
CA$24.68 Million
≈ $17.86 Million
-5.39pp
2017-12-31 73.17% CA$2.36 Million
≈ $1.70 Million
CA$3.22 Million
≈ $2.33 Million
--
pp = percentage points

About Cardiol Therapeutics Inc Class A

TO:CRDL Canada Drug Manufacturers - Specialty & Generic
Market Cap
$118.76 Million
CA$164.17 Million CAD
Market Cap Rank
#18659 Global
#621 in Canada
Share Price
CA$1.47
Change (1 day)
+0.00%
52-Week Range
CA$1.28 - CA$2.23
All Time High
CA$8.13
About

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for… Read more